RXi Pharmaceuticals To Present New Data In Its First Phase 2a Clinical Trial With RXI-109

RXi PharmaceuticalsCorporation (NASDAQ: RXII), a biotechnology company focused on discovering,developing and commercializing innovative therapies addressing major unmetmedical needs using RNA-targeted technologies, today announced that a reviewof the first two enrolled patients' clinical photographs in the first Phase 2aclinical trial (RXI-109-1301), indicate that treatment with the Company's leadclinical candidate, RXI-109, may be effective in suppressing recurrence ofhypertrophic scars at the 3-month time point. Patients will continue to bemonitored through 9 months to evaluate if this outcome persists over time.On September 10^th of this year, the Company announced that based on early1-month observations, the dosing regimen in these trials can be fine-tuned,allowing the Company to more rapidly move forward with treatment optimizationfor the prevention of scarring after surgery. Today's presentation willprovide 3-month photographs from the first two patients enrolled in studyRXI-109-1301 that indicate treatment with RXI-109 shows a clinical benefit.The safety information in this ongoing study to date, continues to confirmthat RXI-109 is well tolerated with no overt systemic side effects.  Localeffects are mild and similar to those seen in the Company's prior Phase 1clinical trials (erythema, occasional, transient burning or stingingsensation). Complete 3-month results from this trial are expected to beavailable in Q1 2015."We are encouraged by the preliminary results in this trial," said Dr. GeertCauwenbergh, President and CEO of RXi Pharmaceuticals. "To date, our Phase 2astudies are providing us with exactly the information for which such studiesare intended, early information on dosing requirements and observation of aclinical effect of the drug. Having this information in hand now should savemoney and time going forward in our clinical development as we willincorporate these learnings into future clinical protocols."The presentation will be webcast today, Tuesday, October 7, 2014 at 10:00 a.m.PST, at the 13^th Annual BIO Investor Forum. The webcast will be available onthe "Investors" section of the Company's website, www.rxipharma.com.